Jim Cramer on what is driving Eli Lilly's stock right now
Speakers
Jim Cramer
— Host, Mad Money
Summary
Jim Cramer previews next week's market-moving earnings and events. He highlights Eli Lilly's reliance on GLP-1 trial data, calls Alphabet his best stock and expects it to romp on earnings, and names McKesson as a wild card that tends to fly when it reports. He also warns Amazon has become a difficult earnings battleground and notes political pressure on healthcare names.
- Cramer says Eli Lilly's stock is driven more by GLP-1 clinical trial data than by earnings.
- He expects Alphabet to romp when it reports and says he bought it back for the charitable trust.
- McKesson is his wild card, with the stock usually flying when it reports.
- Amazon is described as an earnings battleground where rallies are faded and declines extend.
- Political pressure on Humana, UnitedHealth, and CVS is noted as a health care chain risk.
- The segment looks ahead to next week's market-moving moments.
Ideas
GLP-1 data could lift Eli Lilly.
Cramer says Eli Lilly's earnings have not been the main propellant for the stock; new GLP-1 clinical trial reports are the real driver. With the company potentially announcing new data after the close, that catalyst could get the stock rolling higher.
Alphabet could romp on earnings.
Cramer calls Alphabet the best stock in the business and says he bought it back for the charitable trust after seller's remorse. He argues it was wrongly written off as the least of the Magnificent Seven because of Gemini fears, but Gemini, YouTube, Waymo, and Google are all winning, and he expects the stock to romp when it reports.
McKesson earnings usually fly; history repeats.
Cramer's wild card is McKesson: doctors, drug executives, and insurers privately identify drug distributors as the middlemen who make the most and do the least. He expects McKesson's stock to fly again when it reports, as it usually does, betting history repeats itself.
Amazon is earnings battleground; rallies fade.
Cramer warns Amazon has become an earnings battleground. It used to roar on earnings, but now rallies are faded by sellers and if it opens lower it tends to keep going lower, making the stock unattractive into the report.
